Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity

被引:18
|
作者
Rencz, F. [1 ,2 ]
Hollo, P. [3 ]
Karpati, S. [3 ]
Pentek, M. [1 ]
Remenyik, E. [4 ,5 ]
Szegedi, A. [4 ,5 ]
Balogh, O. [1 ]
Heredi, E. [4 ,5 ]
Herszenyi, K. [3 ]
Jokai, H. [3 ]
Brodszky, V. [1 ]
Gulacsi, L. [1 ]
机构
[1] Corvinus Univ Budapest, Dept Hlth Econ, Budapest, Hungary
[2] Semmelweis Univ, Doctoral Sch Clin Med, H-1085 Budapest, Hungary
[3] Semmelweis Univ, Dept Dermatol Venereol & Dermatooncol, H-1085 Budapest, Hungary
[4] Univ Debrecen, Dept Dermatol, Debrecen, Hungary
[5] Univ Debrecen, Dept Dermatol Allergol, Debrecen, Hungary
基金
匈牙利科学研究基金会;
关键词
REPORTED OUTCOMES; ADALIMUMAB TREATMENT; IMPAIRMENT; IMPROVEMENT; MORTALITY; THERAPY; IMPACT; LENGTH; DLQI;
D O I
10.1111/jdv.12884
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundUnrealistic expectations regarding treatments and clinical outcomes may lead to disappointment about therapy and sub-optimal compliance; nonetheless, these expectations have not been studied in psoriasis patients yet. ObjectiveTo evaluate psoriasis patients' subjective future expectations regarding health-related quality of life (HRQOL) and life expectancy, and to explore clinical features associated with under- or overestimating behaviour. MethodsA cross-sectional questionnaire survey of consecutive adult patients with moderate to severe psoriasis was conducted. HRQOL expectations were recorded by applying the EQ-5D descriptive system for 6months ahead and for future ages of 60, 70, 80 and 90 respectively. ResultsIn total, 167 patients (71% males) were included in the analysis with mean age of 50.412.4years and mean EQ-5D score of 0.71 +/- 0.30. Overall 65% had chronic plaque psoriasis, 35% nail psoriasis, 35% scalp involvement, 29% psoriatic arthritis, 9% inverse psoriasis and 5% palmoplantar psoriasis respectively (combinations occurred). Participants expected 0.1 +/- 0.23 mean improvement in EQ-5D within 6months (P<0.001) that achieves the minimum clinically important difference. Overall 37% expected improvement and 13% decline; however, 49% expected no changes in any of the five dimensions of EQ-5D within 6months. Female gender, inverse or palmoplantar involvement and more severe psoriasis were likely associated with higher expectations. Patients at the initiation of their first biological at the time of the survey expected 0.18 +/- 0.24 increase that seems to be realistic compared to the EQ-5D utility gain achieved in randomized controlled trials. Males expected by 2.7 +/- 11.1 more, while females expected by 5.2 +/- 9.3 less life years compared to the average statistical gender- and age-matched life expectancy (P<0.05). Patients who expected to be alive at ages of 60, 70, 80 and 90 scored their future EQ-5D at ages of 60 to 90: 0.59 +/- 0.46, 0.48 +/- 0.41, 0.42 +/- 0.41 and 0.22 +/- 0.47 respectively. ConclusionOur findings highlight the importance of exploring expectations that might help to increase patients' compliance.
引用
收藏
页码:1398 / 1405
页数:8
相关论文
共 50 条
  • [1] SUBJECTIVE EXPECTATIONS REGARDING LIFE EXPECTANCY AND HEALTH-RELATED QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS
    Rencz, F.
    Gulacsi, L.
    Remenyik, E.
    Szegedi, A.
    Hollo, P.
    Karpati, S.
    Pentek, M.
    Brodszky, V
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A611 - A611
  • [2] A long life in good health: subjective expectations regarding length and future health-related quality of life
    Rappange, David R.
    Brouwer, Werner B. F.
    van Exel, Job
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (05): : 577 - 589
  • [3] A long life in good health: subjective expectations regarding length and future health-related quality of life
    David R. Rappange
    Werner B. F. Brouwer
    Job van Exel
    [J]. The European Journal of Health Economics, 2016, 17 : 577 - 589
  • [4] HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS IN BRAZIL
    Lopes, N.
    Gontijo, B.
    Romiti, R.
    Santana, P. K.
    Machado, P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A901 - A902
  • [5] USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
    Lebwohl, M.
    Schenkel, B.
    Han, C.
    Yeilding, N.
    Wang, Y.
    Papp, K. A.
    Krueger, G. G.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A622 - A622
  • [6] Sex-specific differences in health-related quality of life in patients with moderate to severe psoriasis
    Cather, Jennifer C.
    Horn, Elizabeth J.
    Sundaram, Murali
    Bao, Yanjun
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB203 - AB203
  • [7] Ustekinumab improves health-related quality of life in Chinese patients with moderate to severe plaque psoriasis
    Zhu Xue-jun
    Zheng Min
    Song, Michael
    Schenkel, Brad
    Yaung-Kaung Shen
    Wang Bao-xi
    [J]. JOURNAL OF DERMATOLOGY, 2012, 39 : 239 - 239
  • [8] Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan
    Tsai, Tsen-Fang
    Ho, Ji-Chen
    Chen, Yi-Ju
    Hsiao, Pa-Fan
    Lee, Woan-Ruoh
    Chi, Ching-Chi
    Lan, Cheng-Che
    Hui, Rosaline Chung-Yee
    Lin, Yang-Chih
    Yang, Kuo-Chia
    Wong, Tak-Wah
    Sheu, Hamm-Ming
    Hsu, Hsiu-Cheng
    Chu, Gong-Yau
    Huang, Yu-Huei
    [J]. DERMATOLOGICA SINICA, 2018, 36 (04) : 190 - 195
  • [9] Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study
    Dauden, E.
    Pujol, R. M.
    Sanchez-Carazo, J. L.
    Toribio, J.
    Vanaclocha, F.
    Puig, L.
    Yebenes, M.
    Sabater, E.
    Casado, M. A.
    Caloto, M. T.
    Aragon, B.
    [J]. ACTAS DERMO-SIFILIOGRAFICAS, 2013, 104 (09): : 807 - 814
  • [10] Association between clinical response and health-related quality of life outcomes for patients with moderate to severe psoriasis
    Revicki, Dennis
    Menter, Alan
    Saurat, Jean
    Kaul, Martin
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB128 - AB128